Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial will enroll participants that have pneumonia caused by the COVID-19
virus. During the study patients will receive 7 to up to 14 days of defibrotide. After
completing the treatment, participants will have 30 day follow-up check-up to assess for
adverse events and clinical status. This final assessment can be done virtually, by telephone
or electronically (email) if the patient cannot be contacted by phone. No in-person visit is
required.
The hypothesis of this trial is that defibrotide therapy given to patients with severe
SARS-CoV2 ARDS will be safe and associated with improved overall survival, within 28 days of
therapy initiation.